Works matching AU Dreyling, Martin

Results: 142
    1

    Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6).

    Published in:
    Annals of Hematology, 2025, v. 104, n. 4, p. 2317, doi. 10.1007/s00277-025-06355-5
    By:
    • Fuhrmann, Stephan;
    • Nickelsen, Maike;
    • Hasenkamp, Justin;
    • Hüttmann, Andreas;
    • Dreyling, Martin;
    • Kiehl, Michael;
    • Salwender, Hans;
    • Placzek, Marius;
    • Hilgers, Reinhard;
    • Schmitz, Norbert;
    • Glass, Bertram
    Publication type:
    Article
    2
    3

    CAR T-Cells for CNS Lymphoma: Driving into New Terrain?

    Published in:
    Cancers, 2021, v. 13, n. 10, p. 2503, doi. 10.3390/cancers13102503
    By:
    • Karschnia, Philipp;
    • Blobner, Jens;
    • Teske, Nico;
    • Schöberl, Florian;
    • Fitzinger, Esther;
    • Dreyling, Martin;
    • Tonn, Joerg-Christian;
    • Thon, Niklas;
    • Subklewe, Marion;
    • von Baumgarten, Louisa;
    • Schlegel, Uwe
    Publication type:
    Article
    4
    5
    6
    7
    8
    9

    Current Management of Mantle Cell Lymphoma.

    Published in:
    Drugs, 2007, v. 67, n. 12, p. 1689, doi. 10.2165/00003495-200767120-00004
    By:
    • Weigert, Oliver;
    • Unterhalt, Michael;
    • Hiddemann, Wolfgang;
    • Dreyling, Martin
    Publication type:
    Article
    10
    11

    Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.

    Published in:
    Leukemia & Lymphoma, 2024, v. 65, n. 1, p. 14, doi. 10.1080/10428194.2023.2268228
    By:
    • Hess, Georg;
    • Dreyling, Martin;
    • Oberic, Lucie;
    • Gine, Eva;
    • Zinzani, Pier Luigi;
    • Linton, Kim;
    • Vilmar, Adam;
    • Jerkeman, Mats;
    • Chen, Jenny M. H.;
    • Ohler, Anke;
    • Stilgenbauer, Stephan;
    • Thieblemont, Catherine;
    • Lambert, Jonathan;
    • Zilioli, Vittorio Ruggero;
    • Sancho, Juan-Manuel;
    • Jimenez-Ubieto, Ana;
    • Fischer, Luca;
    • Eyre, Toby A.;
    • Keeping, Sam;
    • Park, Julie E.
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18

    Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.

    Published in:
    Leukemia & Lymphoma, 2017, v. 58, n. 12, p. 2824, doi. 10.1080/10428194.2017.1326034
    By:
    • Hess, Georg;
    • Rule, Simon;
    • Jurczak, Wojciech;
    • Jerkeman, Mats;
    • Santucci Silva, Rodrigo;
    • Rusconi, Chiara;
    • Caballero, Dolores;
    • Joao, Cristina;
    • Witzens-Harig, Mathias;
    • Bence-Bruckler, Isabelle;
    • Cho, Seok-Goo;
    • Zhou, Wenjiong;
    • Goldberg, Jenna D.;
    • Trambitas, Cristina;
    • Enny, Christopher;
    • Vermeulen, Jessica;
    • Traina, Shana;
    • Chiou, Chiun-Fang;
    • Diels, Joris;
    • Dreyling, Martin
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30

    High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature.

    Published in:
    Leukemia & Lymphoma, 2013, v. 54, n. 8, p. 1652, doi. 10.3109/10428194.2012.753445
    By:
    • Herold, Tobias;
    • Mulaw, Medhanie A.;
    • Jurinovic, Vindi;
    • Seiler, Till;
    • Metzeler, Klaus H.;
    • Dufour, Annika;
    • Schneider, Stephanie;
    • Kakadia, Purvi M.;
    • Spiekermann, Karsten;
    • Mansmann, Ulrich;
    • Hiddemann, Wolfgang;
    • Buske, Christian;
    • Dreyling, Martin;
    • Bohlander, Stefan K.
    Publication type:
    Article
    31

    The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.

    Published in:
    American Journal of Hematology, 2023, v. 98, n. 11, p. 1699, doi. 10.1002/ajh.27056
    By:
    • Rejeski, Kai;
    • Wang, Yucai;
    • Albanyan, Omar;
    • Munoz, Javier;
    • Sesques, Pierre;
    • Iacoboni, Gloria;
    • Lopez‐Corral, Lucia;
    • Ries, Isabelle;
    • Bücklein, Veit L.;
    • Mohty, Razan;
    • Dreyling, Martin;
    • Baluch, Aliyah;
    • Shah, Bijal;
    • Locke, Frederick L.;
    • Hess, Georg;
    • Barba, Pere;
    • Bachy, Emmanuel;
    • Lin, Yi;
    • Subklewe, Marion;
    • Jain, Michael D.
    Publication type:
    Article
    32

    Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.

    Published in:
    American Journal of Hematology, 2020, v. 95, n. 4, p. 362, doi. 10.1002/ajh.25711
    By:
    • Dreyling, Martin;
    • Santoro, Armando;
    • Mollica, Luigina;
    • Leppä, Sirpa;
    • Follows, George;
    • Lenz, Georg;
    • Won Seog Kim;
    • Nagler, Arnon;
    • Dimou, Maria;
    • Demeter, Judit;
    • Özcan, Muhit;
    • Kosinova, Marina;
    • Bouabdallah, Krimo;
    • Morschhauser, Franck;
    • Stevens, Don A.;
    • Trevarthen, David;
    • Munoz, Javier;
    • Rodrigues, Liana;
    • Hiemeyer, Florian;
    • Miriyala, Ashok
    Publication type:
    Article
    33
    34
    35

    Are Biosimilars the Future of Oncology and Haematology?

    Published in:
    Drugs, 2019, v. 79, n. 15, p. 1609, doi. 10.1007/s40265-019-01193-y
    By:
    • Zinzani, Pier Luigi;
    • Dreyling, Martin;
    • Gradishar, William;
    • Andre, Marc;
    • Esteva, Francisco J.;
    • Boulos, Suliman;
    • González Barca, Eva;
    • Curigliano, Giuseppe
    Publication type:
    Article
    36
    37
    38
    39
    40

    IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S403, doi. 10.1016/S2152-2650(21)01911-X
    By:
    • Schuster, Stephen J.;
    • Dickinson, Michael;
    • Dreyling, Martin;
    • Martinez-Lopez, Joaquin;
    • Kolstad, Arne;
    • Butler, Jason;
    • Ghosh, Monalisa;
    • Popplewell, Leslie;
    • Chavez, Julio C.;
    • Bachy, Emmanuel;
    • Koji Kato;
    • Harigae, Hideo;
    • Kersten, Marie José;
    • Andreadis, Charalambos;
    • Riedell, Peter;
    • Zia, Aiesha;
    • Morisse, Mony Chenda;
    • Fowler, Nathan Hale;
    • Thieblemont, Catherine
    Publication type:
    Article
    41

    Poster: IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S245, doi. 10.1016/S2152-2650(21)01539-1
    By:
    • Schuster, Stephen J.;
    • Dickinson, Michael;
    • Dreyling, Martin;
    • Martinez-Lopez, Joaquin;
    • Kolstad, Arne;
    • Butler, Jason;
    • Ghosh, Monalisa;
    • Popplewell, Leslie;
    • Chavez, Julio C.;
    • Bachy, Emmanuel;
    • Kato, Koji;
    • Harigae, Hideo;
    • Kersten, Marie José;
    • Andreadis, Charalambos;
    • Riedell, Peter;
    • Zia, Aiesha;
    • Morisse, Mony Chenda;
    • Fowler, Nathan Hale;
    • Thieblemont, Catherine
    Publication type:
    Article
    42
    43

    Targeting mTOR/PI3K in Primary CNS Lymphoma (PCNSL).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S107, doi. 10.1016/j.clml.2016.07.155
    By:
    • Korfel, Agnieszka;
    • Schorb, Elisabeth;
    • Schlegel, Uwe;
    • Dimitrijević, Saša Dimitrijević;
    • D'Allonzo, Saana;
    • Dreyling, Martin;
    • Herrlinger, Ullrich;
    • Kiewe, Philipp
    Publication type:
    Article
    44
    45
    46
    47
    48

    APRIL and BAFF: novel biomarkers for central nervous system lymphoma.

    Published in:
    Journal of Hematology & Oncology, 2019, v. 12, n. 1, p. N.PAG, doi. 10.1186/s13045-019-0796-4
    By:
    • Mulazzani, Matthias;
    • Huber, Marion;
    • Borchard, Sabine;
    • Langer, Sigrid;
    • Angele, Barbara;
    • Schuh, Elisabeth;
    • Meinl, Edgar;
    • Dreyling, Martin;
    • Birnbaum, Tobias;
    • Straube, Andreas;
    • Koedel, Uwe;
    • von Baumgarten, Louisa
    Publication type:
    Article
    49
    50

    Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR‐2 retrospective chart review study.

    Published in:
    British Journal of Haematology, 2023, v. 202, n. 4, p. 749, doi. 10.1111/bjh.18519
    By:
    • Hess, Georg;
    • Dreyling, Martin;
    • Oberic, Lucie;
    • Gine, Eva;
    • Zinzani, Pier Luigi;
    • Linton, Kim;
    • Vilmar, Adam;
    • Jerkeman, Mats;
    • Chen, Jenny M. H.;
    • Ohler, Anke;
    • Stilgenbauer, Stephan;
    • Thieblemont, Catherine;
    • Lambert, Jonathan;
    • Zilioli, Vittorio Ruggero;
    • Sancho, Juan‐Manuel;
    • Jiménez‐Ubieto, Ana;
    • Fischer, Luca;
    • Eyre, Toby A.;
    • Keeping, Sam;
    • Park, Julie E.
    Publication type:
    Article